Advertisement

AAPS PharmSciTech

, Volume 19, Issue 8, pp 3770–3777 | Cite as

Preparation and Characterization of an Oral Vaccine Formulation Using Electrosprayed Chitosan Microparticles

  • Jorge Alberto S. Moreno
  • Danai-Anastasia Panou
  • Karen Stephansen
  • Ioannis S. Chronakis
  • Anja Boisen
  • Ana C. Mendes
  • Line Hagner Nielsen
Research Article
  • 78 Downloads

Abstract

Chitosan particles loaded with the antigen ovalbumin (OVA) and the adjuvant Quil-A were produced by electrospray, using mixtures of water/ethanol/acetic acid as a solvent. Three different chitosans designed as HMC+70, HMC+85, and HMC+90 (called as 705010, 855010, and 905010) were tested and its efficacy to be used in oral vaccine delivery applications was investigated. The morphology, size, and zeta potential of the produced particles were investigated, together with the encapsulation efficiency and release of OVA from the three chitosan formulations. Moreover, the mucoadhesion and cytotoxicity of the chitosan microparticles was examined. All the three formulations with OVA and Quil-A were in the micrometer size range and had a positive zeta potential between 46 and 75 mV. Furthermore, all the three formulations displayed encapsulation efficiencies above 80% and the release of OVA over a period of 80 h was observed to be between 38 and 47%. None of the developed formulations exhibited high mucoadhesive properties, either cytotoxicity. The formulation prepared with HMC+70, OVA, and Quil-A had the highest stability within 2 h in buffer solution, as measured by dynamic light scattering. The electrosprayed formulation consisting of HMC+70 with OVA and Quil-A showed to be the most promising as an oral vaccine system.

KEY WORDS

electrohydrodynamics polysaccharide particles ovalbumin Quil-A 

Notes

Funding Information

This study received support from The Danish National Research Foundation (Project DNRF122) and Villum Foundation’s Center (Grant No. 9301) for Intelligent Drug Delivery and Sensing Using Microcontainers and Nanomechanics (IDUN). Line Hagner Nielsen received financial support from the Danish Research Council for Technology and Production (FTP), Project DFF-4004-00120B. Furthermore, this study received financial support from the European Union’s Seventh Framework Programme for research, technological development, and demonstration under grant agreement no. 613931. Furthermore, Jorge Alberto S. Moreno received financial support from the Consejo Nacional de Ciencia y Tecnología (CONACYT) and the Instituto de Innovación y Transferencia de Tecnología (I2T2).

References

  1. 1.
    Foged C. Subunit vaccines of the future: the need for safe, customized and optimized particulate delivery systems. Ther Deliv. 2011;2(8):1057–77 Available from: http://www.ncbi.nlm.nih.gov/pubmed/22826868.CrossRefPubMedGoogle Scholar
  2. 2.
    Gebril A, Alsaadi M, Acevedo R, Mullen AB, Ferro VA. Optimizing efficacy of mucosal vaccines. Expert Rev Vaccines. 2012;11(9):1139–55 Available from: http://informahealthcare.com/doi/abs/10.1586/erv.12.81%5Cn. http://www.ncbi.nlm.nih.gov/pubmed/23151169.CrossRefPubMedGoogle Scholar
  3. 3.
    Davitt CJH, Lavelle EC. Delivery strategies to enhance oral vaccination against enteric infections. Adv Drug Deliv Rev. 2015;91:52–69 Available from: http://www.ncbi.nlm.nih.gov/pubmed/25817337.CrossRefPubMedGoogle Scholar
  4. 4.
    Rizwan SB, McBurney WT, Young K, Hanley T, Boyd BJ, Rades T, et al. Cubosomes containing the adjuvants imiquimod and monophosphoryl lipid A stimulate robust cellular and humoral immune responses. J Control Release. 2013;165(1):16–21. Available from:.  https://doi.org/10.1016/j.jconrel.2012.10.020.CrossRefPubMedGoogle Scholar
  5. 5.
    Wack A, Rappuoli R. Vaccinology at the beginning of the 21st century. Curr Opin Immunol. 2005;17(4 SPEC. ISS):411–8.CrossRefPubMedGoogle Scholar
  6. 6.
    Fujkuyama Y, Tokuhara D, Kataoka K, Gilbert RS, McGhee JR, Yuki Y, et al. Novel vaccine development strategies for inducing mucosal immunity. Expert Rev Vaccines. 2012;11(3):367–79 Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3315788&tool=pmcentrez&rendertype=abstract.CrossRefPubMedCentralPubMedGoogle Scholar
  7. 7.
    Mishra N, Goyal AK, Tiwari S, Paliwal R, Paliwal SR, Vaidya B, et al. Recent advances in mucosal delivery of vaccines: role of mucoadhesive/biodegradable polymeric carriers. Expert Opin Ther Pat. 2010;20(5):661–79 Available from: http://www.ncbi.nlm.nih.gov/pubmed/20345332.CrossRefPubMedGoogle Scholar
  8. 8.
    des Rieux A, Fievez V, Garinot M, Schneider YJ, Preat V. Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J Control Release. 2006;116(1):1–27.CrossRefPubMedGoogle Scholar
  9. 9.
    Van der Lubben IM, Verhoef JC, Borchard G, Junginger HE. Chitosan for mucosal vaccination. Adv Drug Deliv Rev. 2001;52(2):139–44.CrossRefPubMedGoogle Scholar
  10. 10.
    Singh B, Maharjan S, Cho KH, Cui LH, Park IK, Choi YJ, et al. Chitosan-based particulate systems for the delivery of mucosal vaccines against infectious diseases. Int J Biol Macromol. 2018;110:54–64. Available from:.  https://doi.org/10.1016/j.ijbiomac.2017.10.101.CrossRefPubMedGoogle Scholar
  11. 11.
    Rinaudo M. Chitin and chitosan: properties and applications. Prog Polym Sci. 2006;31:603–32.CrossRefGoogle Scholar
  12. 12.
    Illum L, Jabbal-Gill I, Hinchcliffe M, Fisher AN, Davis SS. Chitosan as a novel nasal delivery system for vaccines. Adv Drug Deliv Rev. 2001;51(1–3):81–96.CrossRefPubMedGoogle Scholar
  13. 13.
    Nishimura K, Nishimura S, Nishi N, Numata F, Tone Y, Tokura S, et al. Adjuvant activity of chitin derivatives in mice and guinea-pigs. Vaccine. 1985;3(5):379–84.CrossRefPubMedGoogle Scholar
  14. 14.
    Ahmed TA, Aljaeid BM. Preparation, characterization, and potential application of chitosan, chitosan derivatives, and chitosan metal nanoparticles in pharmaceutical drug delivery. Drug Des Devel Ther. 2016;10:483–507.CrossRefPubMedCentralPubMedGoogle Scholar
  15. 15.
    Zamani M, Prabhakaran MP, Ramakrishna S. Advances in drug delivery via electrospun and electrosprayed nanomaterials. Int J Nanomedicine. 2013;8:2997–3017.PubMedCentralPubMedGoogle Scholar
  16. 16.
    García-Moreno PJ, Özdemir N, Stephansen K, Mateiu RV, Echegoyen Y, Lagaron JM, et al. Development of carbohydrate-based nano-microstructures loaded with fish oil by using electrohydrodynamic processing. Food Hydrocoll. 2017;69:273–85.CrossRefGoogle Scholar
  17. 17.
    Xie J, Wang C-H. Encapsulation of proteins in biodegradable polymeric microparticles using electrospray in the Taylor cone-jet mode. Biotechnol Bioeng. 2007;97(5):1278–90 [cited 2016 Jun 24] Available from: http://doi.wiley.com/10.1002/bit.21334.CrossRefPubMedGoogle Scholar
  18. 18.
    Gallovic MD, Schully KL, Bell MG, Elberson MA, Palmer JR, Darko CA, et al. Acetalated dextran microparticulate vaccine formulated via coaxial electrospray preserves toxin neutralization and enhances murine survival following inhalational bacillus anthracis exposure. Adv Healthc Mater. 2016;5(20):2617–27.CrossRefPubMedGoogle Scholar
  19. 19.
    Lee Y-H, Mei F, Bai M-Y, Zhao S, Chen D-R. Release profile characteristics of biodegradable-polymer-coated drug particles fabricated by dual-capillary electrospray. J Control Release. 2010;145:58–65.CrossRefPubMedGoogle Scholar
  20. 20.
    Arya N, Chakraborty S, Dube N, Katti DS. Electrospraying: a facile technique for synthesis of chitosan-based micro/nanospheres for drug delivery applications. J Biomed Mater Res B Appl Biomater. 2009;88B(1):17–33.CrossRefGoogle Scholar
  21. 21.
    Junkins RD, Gallovic MD, Johnson BM, Collier MA, Watkins-Schulz R, Cheng N, et al. A robust microparticle platform for a STING-targeted adjuvant that enhances both humoral and cellular immunity during vaccination. J Control Release. 2018;270:1–13 Available from: http://linkinghub.elsevier.com/retrieve/pii/S016836591731026X.CrossRefPubMedGoogle Scholar
  22. 22.
    Suksamran T, Opanasopit P, Rojanarata T, Ngawhirunpat T, Ruktanonchai U, Supaphol P. Biodegradable alginate microparticles developed by electrohydrodynamic spraying techniques for oral delivery of protein. J Microencapsul. 2009;26(7):563–70.CrossRefPubMedGoogle Scholar
  23. 23.
    Suksamran T, Ngawhirunpat T, Rojanarata T, Sajomsang W, Pitaksuteepong T, Opanasopit P. Methylated N-(4-N,N-dimethylaminocinnamyl) chitosan-coated electrospray OVA-loaded microparticles for oral vaccination. Int J Pharm. 2013;448(1):19–27. Available from:.  https://doi.org/10.1016/j.ijpharm.2013.03.015.CrossRefPubMedGoogle Scholar
  24. 24.
    Moreno JAS, Mendes AC, Stephansen K, Engwer C, Goycoolea FM, Boisen A, et al. Development of electrosprayed mucoadhesive chitosan microparticles. Carbohydr Polym. 2018;190:240–7.CrossRefPubMedGoogle Scholar
  25. 25.
    Konnings S, Copland MJ, Davies NM, Rades T. A method for the incorporation of ovalbumin into immune stimulating complexes prepared by the hydration method. Int J Pharm. 2002;241(2):385–9.CrossRefPubMedGoogle Scholar
  26. 26.
    Mantle M, Allen A. A colorimetric assay for glycoproteins based on the periodic acid/Schiff stain. Biochem Soc Trans. 1978;6(3):607–9.CrossRefPubMedGoogle Scholar
  27. 27.
    Kilcoyne M, Gerlach JQ, Farrell MP, Bhavanandan VP, Joshi L. Periodic acid-Schiff’s reagent assay for carbohydrates in a microtiter plate format. Anal Biochem. 2011;416:18–26.CrossRefPubMedGoogle Scholar
  28. 28.
    Sjölander A, Cox JC. Uptake and adjuvant activity of orally delivered saponin and ISCOM(TM) vaccines. Adv Drug Deliv Rev. 1998;34(2–3):321–38.CrossRefPubMedGoogle Scholar
  29. 29.
    Kensil C, Wu J, Soltysik S. Structural and immunological characterization of the vaccine adjuvant QS-21. Pharm Biotechnol. 1995;6:525–41.CrossRefPubMedGoogle Scholar
  30. 30.
    von Halling Laier C, Gibson B, van de Weert M, Boyd BJ, Rades T, Boisen A, et al. Spray dried cubosomes with ovalbumin and Quil-A as a nanoparticulate dry powder vaccine formulation. Int J Pharm. 2018;550:35–44 Available from: https://www.sciencedirect.com/science/article/pii/S0378517318306148?via%3Dihub.CrossRefGoogle Scholar
  31. 31.
    McI Mowat A, Smith RE, Donachie AM, Furrie E, Grdic D, Lycke N. Oral vaccination with immune stimulating complexes. Immunol Lett. 1999;65(1–2):133–40.CrossRefGoogle Scholar
  32. 32.
    Bachmann MF, Jennings GT. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol. 2010;10(11):787–96 Available from: http://www.ncbi.nlm.nih.gov/pubmed/20948547.CrossRefPubMedGoogle Scholar
  33. 33.
    Honary S, Zahir F. Effect of zeta potential on the properties of nano-drug delivery systems -a review (part 2). Trop J Pharm Res April J Cit ReportsScience Ed [Internet]. 2013 [cited 2016 Jun 24];12(122):265–265. Available from: http://www.tjpr.org
  34. 34.
    Jiang L, Duan H, Ji X, Wang T, Wang Y, Qiu J. Application of a simple desolvation method to increase the formation yield, physical stability and hydrophobic drug encapsulation capacity of chitosan-based nanoparticles. Int J Pharm. 2018;545(1–2):117–27 Available from: http://linkinghub.elsevier.com/retrieve/pii/S0378517318301893.CrossRefPubMedGoogle Scholar
  35. 35.
    Vela Ramirez JE, Sharpe LA, Peppas NA. Current state and challenges in developing oral vaccines. Adv Drug Deliv Rev. 2017;114:116–31. Available from:.  https://doi.org/10.1016/j.addr.2017.04.008.CrossRefPubMedCentralPubMedGoogle Scholar
  36. 36.
    Aguila A, Donachie AM, Peyre M, McSharry CP, Sesardic D, Mowat AM. Induction of protective and mucosal immunity against diphtheria by a immune stimulating complex (ISCOMS) based vaccine. Vaccine. 2006;24(24):5201–10.CrossRefPubMedGoogle Scholar
  37. 37.
    Mowat AM, Donachie AM, Reid G, Jarrett O. Immune-stimulating complexes containing Quil A and protein antigen prime class I MHC-restricted T lymphocytes in vivo and are immunogenic by the oral route. Immunology. 1991;72(3):317–22 Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1384389&tool=pmcentrez&rendertype=abstract.PubMedCentralPubMedGoogle Scholar
  38. 38.
    McClements DJ. Encapsulation, protection, and delivery of bioactive proteins and peptides using nanoparticle and microparticle systems: a review. Adv Colloid Interface Sci. 2018;253:1–22. Available from:.  https://doi.org/10.1016/j.cis.2018.02.002.CrossRefPubMedGoogle Scholar
  39. 39.
    Fukui Y, Maruyama T, Iwamatsu Y, Fujii A, Tanaka T, Ohmukai Y, et al. Preparation of monodispersed polyelectrolyte microcapsules with high encapsulation efficiency by an electrospray technique. Colloids Surf A Physicochem Eng Asp. 2010;370(1–3):28–34. Available from:.  https://doi.org/10.1016/j.colsurfa.2010.08.039.CrossRefGoogle Scholar
  40. 40.
    Nath SD, Son S, Sadiasa A, Min YK, Lee BT. Preparation and characterization of PLGA microspheres by the electrospraying method for delivering simvastatin for bone regeneration. Int J Pharm. 2013;443(1–2):87–94. Available from:.  https://doi.org/10.1016/j.ijpharm.2012.12.037.CrossRefPubMedGoogle Scholar
  41. 41.
    Myschik J, Eberhardt F, Rades T, Hook S. Immunostimulatory biodegradable implants containing the adjuvant Quil-A - part I: physicochemical characterisation. J Drug Target. 2008;16(3):213–23.CrossRefPubMedGoogle Scholar
  42. 42.
    Gordon S, Saupe A, McBurney W, Rades T, Hook S. Comparison of chitosan nanoparticles and chitosan hydrogels for vaccine delivery. J Pharm Pharmacol. 2008;60(12):1591–600.CrossRefPubMedGoogle Scholar
  43. 43.
    van der Lubben IM, Verhoef JC, van Aelst AC, Borchard G, Junginger HE. Chitosan microparticles for oral vaccination: preparation, characterization and preliminary in vivo uptake studies in murine Peyer’s patches. Biomaterials. 2001;22(7):687–94.CrossRefPubMedGoogle Scholar
  44. 44.
    Kaneko K, McDowell A, Ishii Y, Hook S. Characterization and evaluation of stabilized particulate formulations as therapeutic oral vaccines for allergy. J Liposome Res [Internet]. 2017;1–9. Available from: https://www.tandfonline.com/doi/full/10.1080/08982104.2017.1370472.
  45. 45.
    Dhawan S, Singla AK, Sinha VR. Evaluation of mucoadhesive properties of chitosan microspheres prepared by different methods. AAPS PharmSciTech. 2004;5(4):e67.CrossRefPubMedGoogle Scholar
  46. 46.
    Mackie AR, Goycoolea FM, Menchicchi B, Caramella CM, Saporito F, Lee S, et al. Innovative methods and applications in mucoadhesion research. Macromol Biosci. 2017;17(8):1–32.CrossRefGoogle Scholar
  47. 47.
    Kumar A, Vimal A, Kumar A. Why chitosan? From properties to perspective of mucosal drug delivery. Int J Biol Macromol. 2016;91:615–22. Available from:.  https://doi.org/10.1016/j.ijbiomac.2016.05.054.CrossRefPubMedGoogle Scholar
  48. 48.
    Loh JW, Saunders M, Lim LY. Cytotoxicity of monodispersed chitosan nanoparticles against the Caco-2 cells. Toxicol Appl Pharmacol. 2012;262(3):273–82. Available from:.  https://doi.org/10.1016/j.taap.2012.04.037.CrossRefPubMedGoogle Scholar
  49. 49.
    Heuking S, Adam-Malpel S, Sublet E, Iannitelli A, Di Stefano A, Borchard G. Stimulation of human macrophages (THP-1) using Toll-like receptor-2 (TLR-2) agonist decorated nanocarriers. J Drug Target. 2009;17(8):662–70.CrossRefPubMedGoogle Scholar
  50. 50.
    Soliman GM, Zhang YL, Merle G, Cerruti M, Barralet J. Hydrocaffeic acid-chitosan nanoparticles with enhanced stability, mucoadhesion and permeation properties. Eur J Pharm Biopharm. 2014;88(3):1026–37. Available from:.  https://doi.org/10.1016/j.ejpb.2014.09.003.CrossRefPubMedGoogle Scholar
  51. 51.
    Loretz B, Bernkop-Schnürch A. In vitro cytotoxicity testing of non-thiolated and thiolated chitosan nanoparticles for oral gene delivery. Nanotoxicology. 2007;1(2):139–48.CrossRefGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2018

Authors and Affiliations

  • Jorge Alberto S. Moreno
    • 1
    • 2
  • Danai-Anastasia Panou
    • 1
  • Karen Stephansen
    • 2
  • Ioannis S. Chronakis
    • 2
  • Anja Boisen
    • 1
  • Ana C. Mendes
    • 2
  • Line Hagner Nielsen
    • 1
  1. 1.Department of Micro and NanotechnologyTechnical University of DenmarkKgs. LyngbyDenmark
  2. 2.Nano-Bio Science Research Group, DTU-FoodTechnical University of DenmarkKgs. LyngbyDenmark

Personalised recommendations